Study Finds Ruxolitinib Effective, Safe for Children With AD

There were no significant safety signals in the younger pediatric population, and 'no treatment-emergent adverse events suggestive of systemic JAK inhibition,' Dr Lawrence Eichenfield said.

Related Keywords

San Diego ,California ,United States ,Norway ,Berlin ,Germany ,Lawrencef Eichenfield ,Thrasyvoulos Tzellos ,European Academy Of Dermatology ,University Of California ,Nordland Hospital ,European Academy ,Global Assessment ,Numerical Rating Scale ,Nordland Hospital Trust ,Dermatitis ,Children ,Child ,Childhood ,Ediatrics ,Kids ,Pain Management ,Dermatology Pediatric ,Atopic Dermatitis ,Adolescent Medicine ,Plasma ,Pruritus ,Pruritis ,Pitch ,Patient Safety ,Rheumatoid Arthritis ,A ,Thrombus ,Leukemia ,Anti Inflammatory Agents ,Arthritis ,Oint Inflammation ,Blood , ,Cancer ,Alignant Neoplasia ,Arcinoma ,Drug Treatment Safety ,Eczema ,Europe ,European ,Hea ,